Fennec Pharmaceuticals (FENC) Common Equity (2010 - 2025)
Fennec Pharmaceuticals posted quarterly Common Equity of $35.5 million for Q4 2025, up 704.09% year-on-year from $4.4 million in Q4 2024, and up 889.67% on a QoQ basis from -$4.5 million in Q3 2025.
Fennec Pharmaceuticals (FENC) has 16 years of Common Equity data on file, last reported at $35.5 million in Q4 2025.
- For the quarter ending Q4 2025, Common Equity rose 704.09% year-over-year to $35.5 million; the trailing twelve-month figure through Dec 2025 stood at $35.5 million (up 704.09% YoY), and the FY2025 full-year result was $35.5 million, up 704.09% from the prior year.
- Common Equity for Q4 2025 stood at $35.5 million, up from -$4.5 million in the prior quarter.
- Across five years, Common Equity topped out at $35.5 million in Q4 2025 and bottomed at -$11.6 million in Q4 2023.
- The 5-year median for Common Equity is -$2.0 million (2022), against an average of $3.6 million.
- The widest annual swing landed in 2023, when Common Equity sank 475.84%; it then surged 704.09% in 2025.
- A 5-year view of Common Equity shows it stood at $15.8 million in 2021, then slumped by 116.29% to -$2.6 million in 2022, then plunged by 352.39% to -$11.6 million in 2023, then surged by 49.48% to -$5.9 million in 2024, then soared by 704.09% to $35.5 million in 2025.
- The last three Common Equity figures came in at $35.5 million (Q4 2025), -$4.5 million (Q3 2025), and -$7.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn | 35.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 35.47 Mn |
| Sep 30, 2025 | -4.49 Mn |
| Jun 30, 2025 | -7.46 Mn |
| Mar 31, 2025 | -5.88 Mn |
| Dec 31, 2024 | -5.87 Mn |
| Sep 30, 2024 | -5.17 Mn |
| Jun 30, 2024 | -1.36 Mn |
| Mar 31, 2024 | 3.01 Mn |
| Dec 31, 2023 | -11.62 Mn |
| Sep 30, 2023 | -10.53 Mn |
| Jun 30, 2023 | -9.73 Mn |
| Mar 31, 2023 | -7.34 Mn |
| Dec 31, 2022 | -2.57 Mn |
| Sep 30, 2022 | 2.80 Mn |
| Jun 30, 2022 | 8.54 Mn |
| Mar 31, 2022 | 12.52 Mn |
| Dec 31, 2021 | 15.77 Mn |
| Sep 30, 2021 | 19.01 Mn |
| Jun 30, 2021 | 22.28 Mn |
| Mar 31, 2021 | 24.93 Mn |
| Dec 31, 2020 | 29.07 Mn |
| Sep 30, 2020 | 31.19 Mn |
| Jun 30, 2020 | 36.13 Mn |
| Mar 31, 2020 | 8.46 Mn |
| Dec 31, 2019 | 11.88 Mn |
| Sep 30, 2019 | 15.00 Mn |
| Jun 30, 2019 | 16.48 Mn |
| Mar 31, 2019 | 19.21 Mn |
| Dec 31, 2018 | 21.31 Mn |
| Sep 30, 2018 | 22.86 Mn |
| Jun 30, 2018 | 24.86 Mn |
| Mar 31, 2018 | 25.66 Mn |
| Dec 31, 2017 | 26.76 Mn |
| Sep 30, 2017 | 8.86 Mn |
| Jun 30, 2017 | 9.68 Mn |
| Mar 31, 2017 | 2.86 Mn |
| Dec 31, 2016 | 3.57 Mn |
| Sep 30, 2016 | 4.22 Mn |
| Jun 30, 2016 | 4.65 Mn |
| Mar 31, 2016 | 243,000.00 |
| Dec 31, 2015 | 548,000.00 |
| Sep 30, 2015 | 1.02 Mn |
| Jun 30, 2015 | 1.11 Mn |
| Mar 31, 2015 | 826,000.00 |
| Dec 31, 2014 | 613,000.00 |
| Sep 30, 2014 | -3.23 Mn |
| Jun 30, 2014 | -4.66 Mn |
| Mar 31, 2014 | -4.33 Mn |
| Dec 31, 2013 | -1.46 Mn |
| Sep 30, 2013 | -4.13 Mn |
| Jun 30, 2013 | -2.43 Mn |
| Mar 31, 2013 | -9.07 Mn |
| Dec 31, 2012 | -4.96 Mn |
| Sep 30, 2012 | 1.28 Mn |
| Jun 30, 2012 | 2.05 Mn |
| Mar 31, 2012 | 2.60 Mn |
| Dec 31, 2011 | -120,000.00 |
| Sep 30, 2011 | -3.67 Mn |
| Jun 30, 2011 | -684,000.00 |
| Mar 31, 2011 | -283,000.00 |
| Dec 31, 2010 | -4.93 Mn |